This paper is only available as a PDF. To read, Please Download here.
Abstract
The efficacy and safety of auranofin, an oral gold compound, were investigated for
the treatment of patients with active early rheumatoid arthritis (RA). The 48 patients
enrolled in the study had RA that satisfied the diagnostic standards set in 1987 by
the American College of Rheumatology, was of less than 5 years' duration, and was
of stage I or II and class 1 or 2 according to the Steinbrocker system. Auranofin
3 mg was administered orally twice daily for 12 months. All patients also received
nonsteroidal anti-inflammatory drugs as a basic therapy. Some patients also received
steroids, although the dose was limited to <5 mg/d prednisolone equivalent. No other
disease-modifying antirheumatic drug (DMARD) was administered. On the first day of
the trial and after 3, 6, and 12 months of treatment, clinical symptoms, modified
Lansbury index, C-reactive protein, erythrocyte sedimentation rate, rheumatoid factor,
and the patients' assessments of severity of pain, judged using a visual analog scale,
were evaluated. All of these measurements had improved significantly after 12 months
of treatment. Moreover, no adverse events were observed during the treatment period.
Therefore, the results confirm that auranofin is an effective and safe DMARD and is
useful as a first-line therapy in the treatment of patients with RA.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- L'aurotherapie dans les rheumatisms chroniques.Bull Soc Med Hop Paris. 1929; 53: 323
- Gold therapy in rheumatoid arthritis. Final report of a multicenter controlled trial.Ann Rheum Dis. 1961; 20: 315-324
- Pulmonary fibrosis associated with hypersensitivity to gold salts.BMJ. 1976; 1: 1444
- Pulmonary damage associated with sodium aurothiomalate therapy.J Rheumatol. 1977; 3: 181-182
- Relationship of gold and penicillamine therapy to diffuse interstitial lung disease.Ann Rheum Dis. 1981; 40: 136-141
- Diffuse interstitial lung disease associated with hypersensitivity to gold salt.Clin Exp Rheumatol. 1985; 3 (Letter): 181-182
- A multicentre controlled trial of the effects of different dosages of gold therapy, followed by a maintenance dosage.Agents Actions. 1976; 6: 355-363
- A double-blind trial of high versus conventional doses of gold salts for rheumatoid arthritis.Arthritis Rheum. 1977; 20: 1473-1480
- Radiographic evaluation of the course of articular disease.Clin Rheum Dis. 1983; 9: 541-557
- Radiographic changes in early rheumatoid disease.Ann Rheum Dis. 1977; 36: 71-73
- Auranofin. New oral gold compound for treatment of rheumatoid arthritis.Ann Rheum Dis. 1976; 35: 251-257
- Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes.J Med Chem. 1972; 15: 1095-1098
- Comparative pharmacokinetics of parenteral and oral gold compounds.J Rheumatol. 1982; 9 (Suppl 8): 99-109
- Chrysotherapy in rheumatoid arthritis with particular emphasis on the effect of chrysotherapy on radiographical changes and on the optimal time of initiation of therapy.Scand J Rheumatol. 1980; 34 (Suppl): 1-56
- Auranofin (SK&F) in early rheumatoid arthritis: Results from a 24-month double-blind, placebo-controlled study. Effect on clinical and biochemical assessments.Scand J Rheumatol. 1989; 18: 251-260
- Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double-blind, placebo-controlled study.J Rheumatol. 1988; 15: 1747-1754
- A controlled trial of gold salt therapy in rheumatoid arthritis.Arthritis Rheum. 1973; 16: 353-358
- Therapeutic criteria in rheumatoid arthritis.JAMA. 1949; 140: 659-662
- Studies of the suspension stability of the blood in pulmonary tuberculosis.Acta Med Scand. 1920; 54: 247-282
- The latex fixation test: Application to the serologic diagnosis of rheumatoid arthritis.Am J Med. 1956; 21: 888-892
- Serological reaction in pneumonia with a non protein somatic fraction of pneumococcus.J Exp Med. 1930; 52: 561-571
- Nonsteroidal antiinflammatory drug-induced ulcers: Management by traditional therapies.Gastroenterology. 1989; 96 (Suppl): 662-674
- Epidemiologic survey of upper gastrointestinal disorders caused by nonsteroidal anti-inflammatory agents.Riumachi. 1991; 31 (In Japanese): 96-111
- Therapy of rheumatoid arthritis. A pyramidal plan.Postgrad Med. 1972; 51: 31-39
- Remodeling the pyramid—a concept whose time has come.J Rheumatol. 1989; 16: 565-567
- Reevaluating the therapeutic approach to rheumatoid arthritis: The “Sawtooth” strategy.J Rheumatol. 1990; 17 (Suppl 22): 12-15
- Long term efficacy and safety of auranofin: A review of clinical experience.Scand J Rheumatol. 1986; 63 (Suppl): 67-78
- One year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis.J Rheumatol. 1985; 12: 60-67
- An analysis of worldwide safety experience with auranofin.J Rheumatol. 1985; 12: 695-699
Article info
Identification
Copyright
© 1995 Published by Elsevier Inc.
